



Effects of Antipsychotic Drugs on Memory and Attention in Schizophrenia

Junghee Lee Ph.D., and Sohee Park Ph.D.

Department of Psychology and the Center for Integrative and Cognitive Neuroscience, Vanderbilt University, TN, USA

Abstract

Neurocognitive deficits are cardinal features of schizophrenia, and are important predictors of functional outcome. In this article, we focus on the effects of antipsychotic drug treatment on two key cognitive symptoms, those of attention and memory. A review of the relevant literature was conducted in order to evaluate the efficacy of typical and atypical antipsychotic drugs on the cognitive impairments exhibited by schizophrenic patients. Our review suggests that atypical antipsychotic drugs more effectively ameliorate cognitive impairments than do typical antipsychotic drugs, and that each atypical antipsychotic drug exerts selective effects on attention and memory. In addition, we offer a brief survey of unconventional and novel treatments for neurocognitive symptoms.

Key words: Schizophrenia, Antipsychotic treatment, Memory, Attention.

[Psychiatry Invest 2006; 3 (1):55-65]

Introduction

Neurocognitive deficits, including abnormalities in

attention, memory, executive functions, perception, motor functioning, and language processing, are essential features of schizophrenia. The fundamental role played by neurocognitive impairments in schizophrenia had already been recognized and accurately portrayed by the turn of the 20th century. For example, on the basis of clinical observations, Kraepelin described a broad range of impairments, including deficits in “mental efficiency”, “train of thought”, and “association experiments”, functions that appear analogous to modern conceptualizations of attention, working memory, and executive functions, respectively.¹ However, despite these early insights and the pervasive presence of neurocognitive deficits in schizophrenia, cognitive abnormalities tended to be overshadowed by more conspicuously psychotic clinical symptoms, such as hallucinations and delusions.

More recently, interest in understanding the cognitive aspects of schizophrenic symptoms has been renewed, as accumulating evidence suggests that these symptoms lie at the core of the disorder. First of all, studies of neurocognitive deficits in schizophrenics, their relatives, and individuals at high risk for schizophrenia suggest that neurocognitive deficits may constitute a vulnerability factor in schizophrenia, and may also be considered biobehavioral markers. Neurocognitive deficits in schizophrenia appear to be present at the onset of psychosis^{2,3} or even during the premorbid phase,⁴ and have also been detected in the relatives of schizophrenic individuals, or individuals at high risk for schizophrenia.^{2,3} Secondly, the alleviation of neu-

Correspondence: Junghee Lee Ph.D. and Sohee Park Ph.D., Department of Psychology and the Center for Integrative and Cognitive Neuroscience, Vanderbilt University, 111, 21st Avenue, South Nashville, TN 37240, USA. Tel: +1-615-322-3435, Fax: +1-615-343-8449, E-mail: jungheele@ucla.edu, sohee.park@vanderbilt.edu

rocognitive symptoms may be the key to improved rehabilitation and social functioning. Neurocognitive deficits have been consistently associated with the social functioning impairments exhibited by schizophrenia patients.^{5,6} They also consistently account for significant variance in measures of social and occupational disability,^{7,8} and this association appears to remain stable over time.⁹ Indeed, functional outcomes have been correlated more closely with the extent of neurocognitive deficits than with the severity of positive or negative symptoms.¹¹ Improvements in neurocognitive deficits lead to improved skills in social problem-solving, improved psychosocial skills, improved community (social and occupational) skills, and improved quality of life.⁷ Among the relevant neurocognitive deficits, secondary memory, immediate verbal memory, sustained attention, and semantic memory are most profoundly related to functional outcomes.⁶ Therefore, improvements in neurocognitive deficits effected by pharmacological or non pharmacological treatments, or a combination thereof, may prove to be of great importance in the rehabilitation of schizophrenia patients. In this paper, we will highlight two of the key cognitive symptoms of schizophrenia, those of memory and attention, and will also conduct a short discussion regarding the effects of antipsychotic drug treatment.

Pharmacological treatments for schizophrenia can be divided into two types: typical and atypical antipsychotic drugs.^{10,13,14} Typical antipsychotic drugs, most notably haloperidol, predominantly block dopamine (DA) receptors of the D2 type in the mesolimbic regions, and tend to effect improvements in positive symptoms, such as delusions and hallucinations. However, the blockade of D2 receptors in subcortical areas, specifically the striatum, is a major factor in the induction of extrapyramidal symptoms (EPS), as well as tardive dyskinesia. Atypical antipsychotic drugs, including clozapine, risperidone, and olanzapine, can be defined as drugs that generate minimal extrapyramidal symptoms (EPS) at doses that yield effective

antipsychotic action.¹⁵ Although all of the currently available antipsychotic medications antagonize D2 dopamine receptors, antipsychotic drugs vary substantially with regard to their pharmacological properties.^{13,14} Typical neuroleptics are generally effective in the amelioration of positive symptoms, but there is little compelling evidence to suggest that they exert similar benefits on negative symptoms¹⁶ or neurocognitive deficits.¹⁷ Robust cognitive improvements have been fairly consistently observed in both respondent and chronic, treatment-resistant schizophrenics after the initiation of atypical antipsychotic drug therapy.^{18,19,20,21,22}

Among the neurocognitive deficits associated with schizophrenia, attention and memory appear to be particularly salient with regard to the progress of the illness, and its outcome. Attention abnormalities, which are considered to be one of the primary cognitive deficits in schizophrenia,^{23,24} can be present even before the onset of the illness,²⁵ and have been linked most closely to global functional impairments and poor outcomes in cases of first-episode schizophrenia.²⁶ For example, sustained attention, or vigilance, is known to predict social problem-solving and skill acquisition.²⁷ Memory deficits have been observed even in patients with less severe generalized deficits.²⁶ Verbal memory seems to be related to a wide range of functional outcomes,²⁷ and verbal memory^{11,28,29} and working memory²⁹ are the strongest predictors of poor community outcomes and impairments in skill learning. Several studies^{12,30} have already reviewed the effects of typical and atypical antipsychotic drugs on general neurocognitive deficits. In this article, we have limited our discussion to the effects of pharmacological therapy on selected areas of neurocognitive deficits, namely those of attention and memory, in schizophrenia. In addition, we have reviewed some unconventional pharmacological treatments.

A comprehensive survey of attention and memory would require a weighty tome, and is, therefore, beyond the scope of this article. Below, we have pre-

sented a practical summary of the conceptualization of attention and memory functions as used in the neuropsychiatric literature. Attention can be divided into the following conceptual components: sustained attention, selective attention and inhibition, and divided attention. Sustained attention involves the maintenance of focused attention over a prolonged period of time, in order to detect infrequent signals. The Continuous Performance Task (CPT) is frequently used to measure sustained attention. Selective attention and inhibition refer to the ability to focus attention on relevant information, while ignoring simultaneously presented irrelevant information that could interfere with the work in progress. The Visual Search and Stroop tasks are widely used to measure selective attention and inhibition. Divided attention can be described as the capacity to divide attentional resources between several simultaneous tasks, when attention is required for the performance of both (all) tasks. The Dual task paradigm is commonly used to assess divided attention.

There are many ways in which memory can be conceptualized and subdivided, and a variety of assessment methods have already been established³¹. Secondary memory, immediate memory span, working memory, and semantic memory are most frequently assessed by neuropsychologists in studies of schizophrenia. Secondary memory refers to the ability to acquire and store information over a prolonged period of time (usually several minutes or longer). For example, individuals may be asked to learn and recall a list of words, passages of text, or complex figures. Immediate memory span refers to the ability to hold a limited amount of information for a brief period of time (usually a few seconds). Digit span forward and visual span forward can be used to measure immediate memory span. Immediate memory differs from working memory. Working memory requires individuals to store information “on-line” for a brief period of time, while manipulating that information to guide behavior. There are several ways in which working memory can

be measured, but digit or visual backward span, delayed response task in auditory, spatial or visual modality, and the n-back task are the most commonly used techniques. Semantic memory refers to the storage of knowledge concerning objects, people, or words, and can be measured via the word fluency task.

Effects of pharmacological treatments on memory and attention

Typical antipsychotic drugs have less impact on neurocognitive deficits and negative symptoms associated with schizophrenia, than on positive symptoms. The short-term administration of typical antipsychotic drugs has been reported to induce impairments in sustained attention^{32,33} and immediate memory span,¹⁷ but these effects decrease with chronic treatment.^{17,32,33} Verbal memory can be improved by the administration of typical antipsychotic drugs.^{34,35} Although conventional antipsychotic drugs have been shown, in a few studies, to improve performance on a few selective tasks, there has been no conclusive evidence of improved secondary memory, semantic memory or attention in schizophrenia as the result of treatment with typical antipsychotic drugs^{27,33,36,37}. A recent study reported that neuropsychological impairments in schizophrenia patients receiving typical neuroleptics appear to remain stable, regardless of baseline characteristics and changes in the patients’ clinical states.³⁸ In addition, the extrapyramidal (EPS) and anticholinergic side effects of typical antipsychotic drugs may exert detrimental effects on cognition.⁴⁹

Although the results were initially inconsistent, several studies have reportedly identified robust cognitive improvements in the cognitive functions of schizophrenics treated with clozapine. Improvements of semantic memory as the result of clozapine treatment have also been consistently reported.^{19,21,36,39,40,41,43,44} Clozapine treatment also resulted in improvements in secondary verbal memory in some studies^{18,21,43,44,45} but not in others.^{36,39,40} Clozapine has been associated with

a positive effect on secondary visual memory^{19,42,43} but some studies have not detected this effect,^{41,45,46} and some have even reported deterioration.⁴⁷ Clozapine is not known to improve verbal working memory.^{36,39,40} A recent study,¹⁸ however, did report an improvement in verbal working memory after 16 weeks of clozapine treatment in a case of treatment-resistant schizophrenia. With regard to immediate memory, Fujii et al.⁴⁸ reported that clozapine had no effect, whereas other studies reported that it resulted in some improvement.^{21,43,44,45} While clozapine clearly exerts beneficial effects on some aspects of memory, it appears to have no effect on attention. Clozapine has been determined to have no effect on divided attention,⁴⁸ sustained attention,⁴⁶ or inhibitory processing⁴⁵ in treatment-resistant schizophrenia patients. It was even reported in one study, to impair selective attention and inhibition,¹⁹ although Gallatley et al.⁵⁰ detected improvements in sustained attention in auditory modality after 6 months of clozapine treatment.

Risperidone has been shown to improve working memory in verbal modality^{37,51} and spatial modality.⁵² Working memory is mediated by a constellation of neural circuitry including the prefrontal cortex.⁵³ The improvements observed in working memory after risperidone treatment are consistent with the recent finding that functional activation in the right prefrontal cortex, supplementary motor area, and posterior parietal cortex was increased during working memory tasks after risperidone had been substituted for a typical antipsychotic drug.⁵⁴ In contrast to the beneficial effects observed in the context of working memory, the effects of risperidone on secondary verbal memory and immediate memory remain somewhat controversial. Risperidone has no effect on immediate memory span.^{51,37} Lindenmayer et al.⁴⁵ reported that schizophrenia patients receiving risperidone treatment performed worse at 12 weeks as compared with baseline values, but Kern et al.⁵⁵ reported that risperidone-treated schizophrenia patients exhibited greater improvement in

secondary verbal memory than did haloperidol-treated patients. Long-term risperidone therapy improved the performance of schizophrenia patients on attention assessments, specifically those involving selective attention and alertness,⁵⁶ but 8 weeks of risperidone treatment was determined to have no effect on sustained attention.⁵⁷ Lindenmayer et al.⁴⁵ also detected no effects of risperidone on inhibitory processing, as measured by the Stroop task.

Olanzapine, which is similar to clozapine, exerts beneficial effects on verbal memory.^{58,59} After 20 weeks of olanzapine treatment, improvements were detected in the verbal memory of treatment-refractory schizophrenia patients.⁵⁸ Harvey et al.⁵⁹ also reported that olanzapine exerted beneficial effects on verbal learning and memory. Cuesta et al.⁶⁰ showed that olanzapine treatment improved inhibitory processing on the Stroop task to a higher degree than did risperidone or typical antipsychotic drugs, but that it had no significant effects on semantic memory or visual memory.

In the case of quetiapine, another atypical antipsychotic drug, the results of two studies are currently available. Velligan et al.⁶¹ reported improvements in semantic memory, inhibitory processing, and verbal memory after 24 weeks of quetiapine treatment. Purdon et al.⁴² also determined that quetiapine exerted beneficial effects on semantic memory and secondary verbal memory.

The diverse pharmacological properties of atypical antipsychotic drugs, and the resulting selective effects of specific atypical antipsychotic drugs on neurocognitive deficits, may have important clinical consequences.^{13,14} A few studies have been conducted in order to evaluate the comparative efficacy of atypical antipsychotic drugs on neurocognitive deficits in schizophrenic patients.^{20,59,62} Purdon et al.⁶² found that olanzapine produced a substantial gain in immediate recall (verbal and visual domains), greater than that observed in conjunction with haloperidol or risperidone treatments. In a recent 14-week, double blind study,²⁰

risperidone treatment was determined to result in huge improvements in the verbal learning memory domain over time, and these improvements were substantially more profound than those associated with either clozapine or haloperidol treatments. However, in the selective attention domain, olanzapine was reported to be much more effective in reducing interference on the Stroop task than was risperidone.⁶⁰ Harvey et al.⁵⁹ demonstrated that, although olanzapine and risperidone improved verbal learning and memory, only risperidone resulted in improvements in semantic memory. A recent review and meta-analysis⁶³ compared the effects of several atypical antipsychotic drugs. In this study, quetiapine and clozapine resulted in more pronounced improvements in semantic memory than did risperidone and quetiapine, and olanzapine had a more profound effect on inhibitory attention than did either clozapine or risperidone. With regard to secondary verbal memory, no differences in efficacy were found among the atypical antipsychotic drugs.

Unconventional and novel treatments

Although the atypical antipsychotic drugs appear to be much more effective than the typical drugs in terms of the alleviation of neurocognitive symptoms, they do not effect a return to normal functioning levels in the majority of schizophrenics. It might, therefore, prove necessary to assess the effects of other adjunctive treatments with atypical antipsychotic drugs in the treatment of schizophrenia. Donepezil has been previously used as an adjunctive treatment to risperidone, in an attempt to increase cholinergic activity at the muscarinic and nicotinic receptors. However, this approach had no effects on cognition, including selective attention, sustained attention, spatial working memory, and verbal memory, in the tested cases of schizophrenia⁶⁴. Norepinephrine plays a significant role in working memory functions in the prefrontal cortex, via its action at the alpha-2a noradrenergic receptors.

Guanfacine, an alpha-2 noradrenergic agonist, has proven very effective in the reversal of working memory deficits in non-human primates.⁶⁵ However, in a 4-week treatment trial conducted by Friedman et al.,⁶⁶ guanfacine treatment adjunctive to neuroleptics resulted in no effects on memory and attention in schizophrenic patients.

A much more controversial and intriguing area, though, is an adjunctive treatment involving essential fatty acids. These treatments are predicated on the membrane hypothesis of schizophrenia, which was proposed by Horrobin et al.⁶⁷ It has been suggested that metabolic abnormalities affecting omega-3 polyunsaturated fatty acids (PUFAs) may constitute a core feature of schizophrenia. Evidence for anomalous fatty acid metabolism has been observed in the frontal cortex,⁶⁸ and also in the cell membranes of red blood cells.⁶⁹ Dietary omega-3 PUFA intake has also been associated with the severity of schizophrenia.⁷⁰ These findings provide a rationale for the treatment of schizophrenia with omega-3 PUFAs. Su et al.⁷¹ reported that a pregnant schizophrenia patient exhibited marked improvements in both positive and negative schizophrenic symptoms after being treated with omega-3 fatty acids. Preliminary studies of schizophrenia patients with short-duration illness have indicated some improvements in symptoms when omega-3 fatty acids were added to the patients' usual medications,^{72,73} but a larger trial⁷⁴ found that omega-3 fatty acid supplementation had no effects with regard to both psychopathological symptoms and cognitive impairments. However, the patients enrolled in Fenton et al.'s study⁷⁴ tended to be older, and the daily diets of the subjects could not be controlled. In order to accurately evaluate the efficacy of omega-3 PUFAs treatment on neurocognitive deficits and other symptoms, more clinical trials will clearly be necessary.

The development of schizophrenia during the reproductive period in a majority of affected patients suggests that this disorder may be somehow related to a

disturbance in the reproductive hormone system.⁷⁵ It has been suggested that estrogen may function as a protective factor in women: the age of onset of schizophrenia is significantly older in women than in men, with a larger and later second peak of onset observed in women after 40-45 years of age.^{76,77} Indeed, estrogen adjunctive treatment has been shown to have a positive impact on psychotic symptoms in female schizophrenia patients.⁷⁸ In normal subjects, some evidence suggests that estrogen levels are related to cognition throughout the menstrual cycle, with high levels of estrogen at the mid-luteal point being associated with better verbal memory, but not spatial ability.^{79,80} A recent study⁸¹ also indicated that, in schizophrenia patients, higher than average estrogen levels are associated with better neuropsychological performance in many areas of cognition, including the areas of attention and memory. Specifically, in this study, no difference was found to exist between patients taking oral contraceptives or those on estrogen-replacement therapy. This suggests that higher levels of either endogenous or exogenous estrogen exerted beneficial effects on cognitive functioning. Future studies regarding the effects of estrogen treatment on neurocognitive deficits in schizophrenia are also clearly warranted.

Other adjunctive pharmacological agents, including anti-anxiety drugs and antidepressants, have been used extensively in the treatment of patients suffering from schizophrenia,⁸² but only a very few studies have examined the effects of these adjunctive pharmacological agents on neurocognitive deficits, in relation to the clinical symptoms of schizophrenia.

Discussion

In summary, studies of the effects of pharmacological treatment on neurocognitive deficits have provided strong evidence that atypical antipsychotic drugs ameliorate neurocognitive deficits more effectively than do typical antipsychotic drugs. The effects of atypical antipsychotic drugs on neurocognitive deficits in schiz-

ophrenia do not appear to be secondary to these drugs' decreased propensity to induce EPS.⁸³ Clozapine has been determined to improve both secondary and semantic memory, but results of studies on the effects of clozapine on working memory and attention have not been conclusive. Risperidone has relatively consistent positive effects on working memory, whereas its beneficial effects on verbal learning and memory and attention have been relatively inconsistent. Olanzapine seems to improve verbal learning and memory and semantic memory, but has no effects on working memory or attention.

Most studies regarding the effects of antipsychotic drugs on neurocognitive deficits have focused primarily on general, global effects, and have not been specific as to which particular characteristics of schizophrenia or pharmacological treatment might be related to the effects of treatment. Because several methodological factors relating to study design have been discussed in detail,^{13,22,62,84} we will briefly mention a few factors here. Several studies have reported sex differences in schizophrenia patients with regard to the progress of the illness, and also in terms of neurocognitive deficits. Some studies have determined that male schizophrenia patients tend to perform worse than female patients on measures of cognitive function,^{85,86} and others have reported opposite findings,^{83,87,88} while others still have detected no such sex differences.⁸⁹ It is clearly possible that schizophrenic men and women may respond differently to pharmacological treatment, but the majority of the currently available studies have not examined sex differences, and the results of many studies are based solely on male patients. Sex differences in the neurocognitive deficits associated with schizophrenia are not consistent, and will require further investigation before any definitive conclusions can be drawn. Other factors, including premorbid adjustment, education, and handedness have been previously associated with neurocognitive deficits,⁹⁰ but the majority of studies regarding the effects of antipsychotic drug treatment

did not deal with these factors. It will be necessary, in the future, to specifically determine the extent to which these factors might influence the effects of antipsychotic drugs in the treatment of schizophrenia.

Neurocognitive studies can bridge the gap between neurobiological mechanisms and the etiology of schizophrenia. The methods employed in cognitive neuroscience, including brain imaging techniques, combined with meticulously designed experiments, may help to clarify exactly what type of memory or attention function a particular pharmacological agent is facilitating or inhibiting. Functional neuroimaging studies⁹¹ typically reveal differences in the activation patterns in the brains of schizophrenics and normal controls during attention or memory tasks. However, it is necessary to probe further, by asking what these patterns of differences might mean. It is also clearly necessary to gather more information about the individual differences in the recruitment of specific neural circuits during tasks as the result of treatment with different pharmacological agents. By combining cognitive neuropsychological, neuropharmacological and clinical approaches, future research into the effects of antipsychotic drug treatments on specific neurocognitive functions will result in a better understanding of schizophrenia and a better outcome for patients who suffer from schizophrenia.

References

1. Kraepelin D, Robertson GM. *Dementia praecox and paraphrenia*. Huntington NY, Kreiger, 1919.
2. Erlenmeyer-Kimling L, Rock D, Roberts SA, Janal M, Kestenbaum C, Cornblatt B, Adamo UH, Gottesman II. 2000. Attention, memory, and motor skills as childhood predictors of schizophrenia-related psychoses: The New York high-risk project. *Am J Psychiatry* 2000; 157:1416-1422.
3. Cornblatt B, Obuchowski M. Update of high-risk research: 1987-1997. *Int Rev Psychiatry* 1997; (4):437-447.
4. Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. *Biol Psychiatry* 2001;50(11):884-897.
5. McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. *Schizophr Res* 2000; 45 (3):175-184.
6. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff"? *Schizophr Bull* 2000; 26 (1): 119-136.
7. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? *Am J Psychiatry*. 1996; 153:321-330.
8. Harvey PD, Howanitz E, Parrella M, White L, Davidson M, Mohs RC, Hoblyn J, Davis KL. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with life-long schizophrenia: a comparison across treatment sites. *Am J Psychiatry* 1998; 155:1080-1086.
9. Dickerson F, Boronow JJ, Ringel N, Parente F. Social functioning and neurocognitive deficits in outpatients with schizophrenia: a 2-year follow-up. *Schizophr Res* 1999; 37: 13-20.
10. Meltzer HY, Park S, Kessler R. Cognition, Schizophrenia, and the Atypical Antipsychotic Drugs. *Proc Natl Acad Sci U S A* 1999; 96 (24):13591-13593.
11. McGurk SR, Moriarty PJ, Harvey PD, Parrella M, White L, Davis KL. The longitudinal relationship of clinical symptoms, cognitive functioning, and adaptive life in geriatric schizophrenia. *Schizophr Res* 2000; 42:47-55.
12. Meltzer HY, McGurk S. The effect of Clozapine, Risperidone, and Olanzapine on cognitive function in schizophrenia. *Schizophr Bull* 1999; 25 (2):233-255.
13. Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. *Schizophr Bull* 1999; 25 (2):201-222.
14. Seeman P. Atypical antipsychotics: Mechanisms of action. *Can J Psychiatry* 2002; 47 (1):27-38.
15. Meltzer HY. The concept of antipsychotic drugs. In den Boer, J. A., Westenberg HGM, van Praag HM. (Eds), *Advances in the Neurobiology of schizophrenia*, Vol. 1 (pp. 265-273). London, Wiley & Sons, 1995.
16. King DJ. Drug treatment of the negative symptoms of schizophrenia. *Eur Neuropsychopharmacol* 1998; 8 (1):33-42.

17. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive function in schizophrenia. *J Abnorm Psychol* 1989; 98:367-380.
18. Galletly CA, Clark CR, McFarlane AC, Weber DL. Effects of clozapine on non-treatment-resistant patients with schizophrenia. *Psychiatr Serv* 1999; 50:101-103.
19. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. *Biol Psychiatry* 1994; 36:717-725.
20. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. *Am J Psychiatry* 2002; 159 (6):1018-1028.
21. Purdon SE, Labelle A, Boulay L. Neuropsychological change in schizophrenia after 6 weeks of clozapine. *Schizophr Res* 2001; 48:57-67.
22. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. *Am J Psychiatry* 2001; 158 (2):176-184.
23. Seidman LJ. Schizophrenia and brain dysfunction: an integration of recent neurodiagnostic findings. *Psychol Bull* 1983; 94 (2):195-238.
24. Nuechterlein KH, Dawson ME. Information processing and attentional functioning in the developmental course of schizophrenic disorders. *Schizophr Bull* 1984; 10:160-203.
25. Cornblatt BA, Keilp JG. Impaired attention, genetics, and the pathophysiology of schizophrenia. *Schizophr Bull* 1994; 20:31-46.
26. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, Pappadopulos E, Willson DF, Alvir JM, Woerner MG, Geisler S, Kane JM, Lieberman JA. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. *Am J Psychiatry* 2000; 157 (4):549-559.
27. Sharma T. Cognitive effects of conventional and atypical antipsychotics in schizophrenia. *Br J Psychiatry. Suppl* 1999; 179 (38):44-51.
28. Addington J, Addington D. Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. *Schizophr Res* 2000; 44:47-56.
29. Liddle PF. Cognitive impairment in schizophrenia: its impact on social functioning. *Acta Psychiatrica Scandi* 2000; 101:11-16.
30. Meltzer HY, Thompson PA, Lee MA, Ranjan R. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. *Neuropsychopharmacology* 1996; 14 (3 Suppl):27S-33S.
31. Lezak MD. *Neuropsychological Assessment*. 3rd ed. King DJ. The effect of neuroleptics on cognitive and psychomotor function. *J Psychiatry* 1990; 157:799-811.
32. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. *Schizophr Bull* 1990; 16 (3): 477-499.
33. Sweeney JA, Hass GL, Keilp JG, Long M. Evaluation of the stability of neuropsychological functioning after acute episodes of schizophrenia: one year follow-up study. *Psychiatry Res* 1991; 38:63-76.
34. Bilder RM, Lipschutz-Broch L, Reiter G, Geisler S, Mayerhoff D, Lieberman JA. Neuropsychological deficits in the early course of first episode schizophrenia. *Schizophr Res* 1991; 5 (3):198-199.
35. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. *Biol Psychiatry* 1993; 34 (10): 702-712.
36. Green MF, Marshall BD Jr, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? *Am J Psychiatry* 1997; 154 (6):799-804.
37. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV. Stability and course of neuropsychological deficits in schizophrenia. *Arch Gen Psychiatry* 2001; 58 (1): 24-32.
38. Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. *J Clin Psychiatry* 1994; 55 (Suppl B):82-87.
39. Lee MA, Jayathilake K, Meltzer HY. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. *Schizophr Res* 1999; 37:1-11.
40. Hoff AL, Faustman WO, Wieneke M, Espinoza S, Costa M, Wolkowitz O, Csernansky JG. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schiz-

- ophrenic inpatients. *Neuropsychopharmacology* 1996; 15 (4):361-369.
41. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. *J Psychiatry Neurosci* 2001; 26 (2):137-149.
 42. Grace J, Bellus SB, Raulin ML, Herz MI, Priest BL, Brenner V, Donnelly K, Smith P, Gunn S. Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. *Psychiatr Serv* 1996; 47 (1):41-45.
 43. Potkin SG, Fleming K, Jin Y, Gulasekaram B. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. *J Clin Psychopharmacol* 2001; 21 (5):479-483.
 44. Lindenmayer JP, Iskander A, Park M, Apergi FS, Czobor P, Smith R, Allen D. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. *J Clin Psychiatry* 1998; 59 (10):521-527.
 45. Daniel DG, Goldberg TE, Weinberger DR, Kleinman JE, Pickar D, Lubick LJ, Williams TS. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. *Am J Psychiatry* 1996; 153 (3):417-419.
 46. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, Schulz SC, Weinberger DR. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. *Br J Psychiatry* 1993; 162: 43-48.
 47. Fujii DE, Ahmed I, Jokumsen M, Compton JM. The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. *J Neuropsychiatry Clin Neurosci* 1997; 9 (2):240-245.
 48. Galletly CA, Clark CR, MacFarlane AC. Treating cognitive dysfunction in patients with schizophrenia. *J Psychiatry Neurosci* 2000; 25 (2):117-124.
 49. Galletly CA, Clark CR, McFarlane AC, Weber DL. The effect of clozapine on the speed and accuracy of information processing in schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 2000; 24 (8):1329-1328.
 50. Rossi A, Mancini F, Stratta P, Mattei P, Gismondi R, Pozzi F, Casacchia M. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. *Acta Psychiatr Scand* 1997; 95 (1):40-43.
 51. McGurk SR, Green MG, Wirshing WC, Ames D, Marshall BD, Marder SM. The effects of risperidone vs. haloperidol on spatial working memory in treatment-resistant schizophrenia. Paper presented at: 51st Annual Meeting of the Society of Biological Psychiatry, New York, 1996
 52. Goldman-Rakic PS. Prefrontal cortical dysfunction in schizophrenia: The relevance of working memory. In B. Carroll Ed. by *Psychopathology and the Brain*. New York: Raven Press; 1991.
 53. Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. *Proc Natl Acad Sci U S A* 1999; 96 (23): 13432-13437.
 54. Kern RS, Green MF, Marshall BD Jr, Wirshing WC, Wirshing D, McGurk SR, Marder SR, Mintz J. Risperidone versus haloperidol on secondary memory: can newer medications aid learning? *Schizophr Bull* 1999; 25 (2):223-232.
 55. Stip E, Lussier I. The effect of risperidone on cognition in patients with schizophrenia. *Can J Psychiatry* 1996; 41 (8 Suppl 2):S35-S40.
 56. Hong KS, Kim JG, Koh HJ, Koo MS, Kim JH, Lee D, Kim E. Effects of risperidone on information processing and attention in first-episode schizophrenia. *Schizophr Res* 2002; 53 (1-2):7-16
 57. Smith RC, Infante M, Singh A, Khandat A. The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. *Int J Neuropsychopharmacol* 2001; 4 (3):239-250.
 58. Harvey PD, Mao L, Napolitano J, Gharabawi G. Cognition in elderly schizophrenic patients: risperidone vs olanzapine. *Eur Psychiatry* 2002; 17 (Suppl 1):192.
 59. Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in schizophrenia: a longitudinal study. *Schizophr Res* 2001; 48:17-28.
 60. Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin R, Miller AL. Does cognitive function improve with quetiapine in comparison to haloperidol? *Schizophr Res* 2002 Jan 15; 53 (3):239-248
 61. Purdon SE, Jones BDW, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefson GD. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol.

- Arch Gen Psychiatry 2000; 57:249-258.
62. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. *Int J Neuropsychopharmacol* 2005; 8 (3):457-472
 63. Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H, White L, Parrella M, Davis KL. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. *Biol Psychiatry* 2002; 51 (5):349-357.
 64. Arnsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. *J Neurosci* 1988; 8 (11):4287-4298.
 65. Friedman JI, Adler DN, Temporini HD, Kemether E, Harvey PD, White L, Parrella M, Davis KL. Guanfacine treatment of cognitive impairment in schizophrenia. *Neuropsychopharmacology* 2001; 25 (3):402-409.
 66. Horrobin DF, Glen AI, Vaddadi K. The membrane hypothesis of schizophrenia. *Schizophr Res* 1994; 30:193-208.
 67. Horrobin DF, Manku MS, Hillman H, Iain A, Glen AIM. 1991. Fatty acid levels in the brains of schizophrenics and normal controls. *Biol Psychiatry* 1991; 30:795-805.
 68. Yao JK, van Kammen DP, Welker JA. Red blood cell membrane dynamics in schizophrenia: II Fatty acid composition. *Schizophr Res* 1994; 13:217-226.
 69. Mellor JE, Laugharne JDE, Peet M. Omega-3 fatty acid supplementation in schizophrenia patients. *Hum Psychopharmacol* 1996; 11:39-46.
 70. Su KP, Shen WW, Huang SY. Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient. *Eur Neuropsychopharmacol* 2001; 11 (4):295-299.
 71. Fenton WS, Hieebln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. *Biol Psychiatry* 2000; 47:8-21.
 72. Puri BK, Richardson AJ. Sustained remission of positive and negative symptoms of schizophrenia after treatment with eicosapentaenoic acid (letter). *Arch Gen Psychiatry* 1998; 55:188-189.
 73. Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. A placebo-controlled trial of omega-3 fatty acid (Ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. *Am J Psychiatry* 2001; 158:2071-2074.
 74. Stevens JR. Schizophrenia: Reproductive hormones and the brain. *Am J Psychiatry* 2002; 159:713-719.
 75. Cyr M, Calon F, Morissette M, Di Paolo T. Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. *J Psychiatry Neurosci* 2002; 27 (1): 12-27.
 76. Lindamer LA, Lohr JB, Harris MJ, Jeste DV. Gender, estrogen, and schizophrenia. *Psychopharmacol Bull* 1997; 33 (2):221-228.
 77. Kulkarni J, Riedel A, de Castella AR, Fitzgerald PB, Rolfe TJ, Taffe J, Burger H. Estrogen-a potential treatment for schizophrenia. *Schizophr Res* 2001; 48 (1):137-144.
 78. Hampson E. Variations in sex-related cognitive abilities across the menstrual cycle. *Brain Cogn* 1990; 14 (1):26-43.
 79. Rosenberg L, Park S. Verbal and spatial functions across the menstrual cycle in healthy young women. *Psychoneuroendocrinology* 2002; 27 (7):835-84
 80. Hoff AL, Kremen WS, Wieneke MH, Lauriello J, Blankfeld HM, Faustman WO, Csernansky JG, Nordahl TE. Association of estrogen levels with neuropsychological performance in women with schizophrenia. *Am J Psychiatry* 2001; 158 (7):1134-1139.
 81. Buchanan RW, Kreyenbuhl J, Zito JM, Lehman A. Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. *Am J Psychiatry* 2002; 159 (6):1035-1043.
 82. Weiser M, Reichenberg A, Rabinowitz J, Kaplan Z, Mark M, Nahon D, Davidson M. Gender differences in premorbid cognitive performance in a national cohort of schizophrenic patients. *Schizophr Res* 2000; 45 (3):185-190.
 83. Purdon SE. Cognitive improvement in schizophrenia with novel antipsychotic medications. *Schizophr Res* 1999; 35 Suppl:S51-S60.
 84. Goldstein JM, Santangelo SL, Simpson JC, Tsuang MT. The role of gender in identifying subtypes of schizophrenia: a latent class analytic approach. *Schizophr Bull* 1990; 16 (2):263-275.
 85. Seidman LJ, Goldstein JM, Goodman JM, Koren D, Turner WM, Faraone SV, Tsuang MT. Sex differences in olfactory identification and Wisconsin Card Sorting performance in schizophrenia: relationship to attention and verbal ability. *Biol Psychiatry* 1997; 15; 42 (2):104-115.
 86. Perlick D, Mattis S, Stastny P, Teresi J. Gender differences

- in cognition in schizophrenia. *Schizophr Res* 1992; 8:69-73.
87. Lewine RR, Walker EF, Shurett R, Caudle J, Haden C. Sex differences in neuropsychological functions among patients with schizophrenia. *Am J Psychiatry* 1996; 153:1178-1184.
88. Minor K, Park S. Spatial working memory: Absence of gender differences in schizophrenia patients and healthy control subjects. *Biol Psychiatry* 1999; 46:1003-1005.
89. Norman RM, Townsend L, Malla AK. Duration of untreated psychosis and cognitive functioning in first-episode patients. *Br J Psychiatry* 2001; 179:340-345.
90. Pearlson GD. Neurobiology of schizophrenia. *Ann Neurol* 2000; 48 (4):556-66.